STOK241220P20000
- 0.00
- 0.000.00%
Stoke Therapeutics Newsroom
Stoke Therapeutics (STOK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
CCORF Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $20
J.P. Morgan Maintains Stoke Therapeutics(STOK.US) With Hold Rating, Raises Target Price to $15
Stoke Therapeutics Shares Are Trading Higher on Possible Continued Strength Following Q3 Reported Financial Results Yesterday. Also, Needham and HC Wainwright & Co. Reiterated Buy Ratings on the Stock.
A Quick Look at Today's Ratings for Stoke Therapeutics(STOK.US), With a Forecast Between $15 to $35
Analysts Conflicted on These Healthcare Names: AnaptysBio (ANAB), Stoke Therapeutics (STOK) and Immatics (IMTX)
Need To Know: Analysts Are Much More Bullish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenues
Stoke Therapeutics' Zorevunersen Shows Promising Efficacy in Reducing Seizures and Improving Quality of Life, Justifying Buy Rating
Stoke Therapeutics Price Target Maintained With a $35.00/Share by HC Wainwright & Co.
Stoke Therapeutics Analyst Ratings
Stoke Therapeutics Reports Q3 Results, Focuses on Phase 3 Study
Stoke Therapeutics | 10-Q: Q3 2024 Earnings Report
Stoke Therapeutics: Promising Growth Potential Backed by Strategic Advancements and Financial Stability
Stoke Therapeutics GAAP EPS of -$0.47 Beats by $0.06, Revenue of $4.89M Beats by $1.29M
Stoke Therapeutics | 8-K: Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
Stoke Therapeutics: Talks With FDA and Global Regulatory Agencies Related to Single Global Phase 3 Study of Zorevunersen Continue to Progress >STOK
Earnings Flash (STOK) STOKE THERAPEUTICS Posts Q3 Revenue $4.9M
Earnings Flash (STOK) STOKE THERAPEUTICS Reports Q3 Loss $-0.47 Per Share
Express News | Stoke Therapeutics Q3 Operating Expenses USD 34.897 Million
Express News | Stoke Therapeutics Q3 Revenue USD 4.894 Million Vs. IBES Estimate USD 3.35 Million